Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Air France-KLM and China Eastern Airlines broaden their joint venture

2018-07-19 reuters
PARIS (Reuters) - Air France-KLM (AIRF.PA) and its stakeholder and business partner China Eastern Airlines (600115.SS) announced plans on Thursday to broaden their joint venture to take in new routes.
AFRAF CHEAF CEA AFLYY 0670

0
Airbus discussing blockbuster sale of US$6bil worth of planes to AirAsia

2018-07-17 thestar.com.my
France-based planemaker is also working on a blockbuster agreement to sell US$23bil worth of aircraft to AirAsia Group Bhd, the continent’s biggest budget carrier, people familiar with the matter said, asking not to be identified discussing private talks. (Brisk sales: An Airbus A350 aircraft flies in formation with Britain’s Red Arrows flying display team at the Farnborough International Airshow in Britain.
ZNH INDIGO C6L CHEAF SINGY CEA 0670 539448 1055 5238 BOE BA SINGF

0
Airbus wins US$9.2b of aircraft orders from Asian carriers

2018-07-16 theedgemarkets
LONDON (July 16): Airbus SE kicked off its sales campaign at this year’s biggest air show by announcing US$9.2 billion of orders from Asian carriers that are augmenting their fleets to meet surging demand for air travel in the region.
ZNH INDIGO C6L CHEAF SINGY CEA 0670 539448 1055 5238 BOE BA SINGF

0
Air France-KLM chairman blames Accor over CEO search delay

2018-07-13 reuters
PARIS (Reuters) - Anne-Marie Couderc, the interim chairman of Air France KLM (AIRF.PA), has blamed AccorHotels (ACCP.PA) for complicating and delaying the airline’s search for a new chief executive, according to an internal memo seen by Reuters.
AFRAF CHEAF CEA AFLYY 0670

0
Air France-KLM chairman blames Accor over CEO search delay

2018-07-13 reuters
PARIS, July 13 (Reuters) - Anne-Marie Couderc, the interim chairman of Air France KLM, has blamed AccorHotels for complicating and delaying the airline’s search for a new chief executive, according to an internal memo seen by Reuters.
AFRAF CHEAF CEA AFLYY 0670

90
Deals of the day-Mergers and acquisitions

2018-07-11 reuters
July 11 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Wednesday:
SCG AVV.CL AV AV.A AV.B BNKXF CHEAF STGPF AV CEA CGC SCTRY 0670 AIVAF BNKXY TWMJF AVV WEED

0
China shares fall, yuan falters on new US tariff threat

2018-07-11 theedgemarkets
SHANGHAI (July 11): China's stocks slumped Wednesday after three days of gains and the yuan weakened as the United States threatened more import duties on Chinese goods, sharply escalating the trade conflict between the world's two biggest economies.
ZNH 0753 AICAF AIRC CHEAF AIRYY CEA 0670 1055

2
Air France-KLM CEO hunt signals industry strategy shift under Macron

2018-07-10 channelnewsasia
The hunt for a new chief executive to lead Air France-KLM, a group hobbled by union resistance to cost-cutting at its French brand, is testing President Emmanuel Macron's resolve for a lighter state touch on the economy.
AFRAF VEOEY CHEAF VEOEF DAL CEA AFLYY 0670

2
Air France-KLM CEO hunt signals industry strategy shift under Macron

2018-07-10 reuters
PARIS (Reuters) - The hunt for a new chief executive to lead Air France-KLM, a group hobbled by union resistance to cost-cutting at its French brand, is testing President Emmanuel Macron’s resolve for a lighter state touch on the economy.
AFRAF VEOEY CHEAF VEOEF DAL CEA AFLYY 0670

0
Air France KLM's traffic rises, transport boss touted as new CEO

2018-07-09 channelnewsasia
Air France KLM , hit by strikes and without a CEO since May, reported higher passenger traffic for June on Monday, while a leading French transport executive was touted as its possible new chief executive.
CHEAF CEA 0670

0
Air France KLM's traffic rises, transport boss touted as new CEO

2018-07-09 reuters
PARIS (Reuters) - Air France KLM (AIRF.PA), hit by strikes and without a CEO since May, reported higher passenger traffic for June on Monday, while a leading French transport executive was touted as its possible new chief executive.
CHEAF CEA 0670

0
New Beijing international airport to start operating in September 2019

2018-07-08 newsinfo.inquirer.net
The new Beijing airport, pictured here in September 2017, will open in September 2019. (Photo by JU HUANZONG / Xinhua vis China Daily)
ZNH CHEAF 0694 CEA 0670 1055

0
China stock market: who will be the winners and losers in the escalating US-China trade row

2018-07-03 scmp
A sliding yuan may hurt airlines, developers and paper companies hard, but bodes well for exporters as it will boost their profitability
ZNH AICAF NDGPY MS.PRE CHEAF AIRYY MS.PRF MS.PRG MS.PRA CEA 0670 1055 NDGPF 0753 MS.PRI AIRC MS.PRK MS

0
New Cebu airport terminal leaves good impression on passengers

2018-07-01 newsinfo.inquirer.net
View of the new MCIA terminal from the outside. It started commercial operations on July 1. —JOSE SANTINO BUNACHITA
CHEAF CEA 0670

2
China blue-chips hit 13-month low as trade fears, falling yuan spook investors

2018-06-27 theedgemarkets
SHANGHAI (June 27): China stocks extended a bruising sell-off on Wednesday, with blue chips slumping to their worst loss in over a year on growing concerns about the economic outlook amid a bitter trade dispute with the United States and a faltering yuan.
ZNH 0753 AICAF AIRC CHEAF AIRYY CEA 0670 1055

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...